The Cooper Companies (COO) Earnings Expected to Grow: Should You Buy?

The Cooper Companies is forecast to report fiscal-quarter results for the period ended October 2025 on December 4 with consensus EPS of $1.11 (+6.7% YoY) and revenue of $1.06 billion (+4.1% YoY). The Zacks consensus EPS for the quarter has been revised down 0.4% over the past 30 days, and the Most Accurate Estimate is below consensus, producing an Earnings ESP of -1.05%, while the stock carries a Zacks Rank #3. The company beat consensus in three of the last four quarters (most recent quarter: $1.10 actual vs. $1.07 expected, +2.8% surprise), but the negative ESP and modest analyst downgrades make an earnings beat less likely and leave the near-term stock reaction uncertain.

Analysis

Market structure: A mildly negative pre-earnings signal (Earnings ESP -1.05%, recent analyst downticks) makes COO a near-term loser relative to peers if numbers or guidance disappoint; direct beneficiaries are larger, diversified ophthalmics/surgical names (ALC, JNJ) that can take share if Cooper’s elective/contact-lens growth softens. Pricing power is tenuous—flat-to-low-single-digit revenue growth (consensus +4.1%) implies limited margin expansion without cost cuts or price increases, pressuring small-mid cap med-tech multiples.

Risk assessment: Tail risks include an FDA manufacturing recall, a material reimbursement shock for contact lenses, or a surprise downward restatement—each could move shares >15% intraday; immediate risk window is ±5 trading days around Dec 4, medium-term (3–12 months) depends on pipeline cadence and any M&A, long-term (>12 months) tied to product approvals and global retail demand recovery. Hidden dependencies: patient replacement cycles, eye-care clinic visit cadence, and FX exposure are underappreciated drivers of revenue-to-EPS conversion.

Trade implications: Tactical plays favor downside protection or modest short exposure into the print. Use put-spreads to limit premium spend (buy Dec monthly 5% OTM / sell 10% OTM) or establish a small cash short (1–3% notional) sized to portfolio volatility; consider a 3-month pair trade long ALC (2–3% weight) vs short COO (2–3%) to capture relative execution risk.

Contrarian angles: Consensus may underweight a clean beat plus upbeat surgical backlog commentary—if COO reports EPS > consensus by >3% and revenue +>2% and raises FY guide, expect a >7% bounce. Conversely, the market may be underpricing recall/regulatory risk; mispricings likely compress within 3–10 trading days post-print, so time decay favors defined-risk options over naked shorts.

Key Decisions for Investors

• Establish a defined-risk bearish trade: buy Dec monthly put spread on COO sized to 1–2% of portfolio (buy 1–2.5% OTM puts, sell 6–8% OTM puts) 5–10 trading days before Dec 4; close within 3 trading days after the print unless fundamentals change. Rationale: captures expected IV skew and limits premium; threshold to add: EPS miss >3% or revenue miss >2%.
• If seeking a relative-value position, initiate a 3-month pair trade long Alcon (ALC) 2–3% vs short Cooper (COO) 2–3%; rebalance or unwind if spread moves >5% in either direction or if COO raises FY guidance by >2%.
• If already long COO, immediately reduce net exposure by 30–50% and sell Dec covered calls ~3–5% OTM to capture premium; re-establish longs only after two consecutive quarters of beats and guide upgrades (>+2% FY).
• Portfolio rotation: Trim 2–4% from elective/optics small-mid cap exposure and reallocate into defensive large-cap healthcare (e.g., JNJ overweight by 1–2%) to reduce idiosyncratic regulatory and discretionary-spend risk over the next 3–6 months.
• Monitor four specific triggers within 48 hours of the print: (1) EPS delta vs consensus ±3%, (2) revenue delta ±2%, (3) FY guide change ±2%, (4) any FDA/manufacturing announcement—act (scale in/out) if any trigger is hit.